{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T10:22:56Z","timestamp":1782814976620,"version":"3.54.5"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T00:00:00Z","timestamp":1683763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Secukinumab is a biologic disease-modifying antirheumatic drug (bDMARD) that has demonstrated efficacy in the treatment of axial spondyloarthritis (axSpA, i.e., ankylosing spondylitis and non-radiographic axSpA) across various clinical trials. However, data of secukinumab in clinical practice is still limited. Here, we aimed to provide real-world data on secukinumab use, effectiveness, and persistence in axSpA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and methods<\/jats:title><jats:p>Retrospective, multicenter study of patients with a diagnosis of axSpA treated with secukinumab at 12 centers up to June 2021 in the Valencian Community (Spain). Information was gathered on BASDAI measurement, pain, patient and physician global assessment (ptGA, phGA) using a 100-mm visual analog scale (VAS), persistence and other secondary variables by treatment line (first, second, and\u2009\u2265\u2009third) for up to 24 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>221 patients were included (69% men; mean age [standard deviation, SD]: 46.7 [12.1] years old). Secukinumab was used as a first-line bDMARD in 38% of patients, as a second-line in 34% and as a \u2265 hird-line in 28%. The percentage of patients achieving low disease activity (BASDAI&amp;lt;4) increased from 9% at baseline to 48% at month 6 and was maintained (49%) up to month 24. Improvements in BASDAI were observed across all treatment lines: in na\u00efve patients (month 6: \u22122.6; month 24: \u22122.7), in second-line (month 6: \u22121.9; month 24: \u22123.1), and in patients on third lines (month 6: \u22121.3; month 24: \u22121.7). Reductions in mean pain VAS (\u221223.3; \u221231.9), ptGA (\u221225.1; \u221231.9) and phGA (\u221225.1; \u221231) were also observed at 6 and 24\u2009months. Secukinumab showed an overall 12-months persistence rate of 70% (95% confidence interval [CI]: 63\u201377%) and a 24-months persistence rate of 58% (95% CI, 51\u201366%). Patients receiving first-line secukinumab had the highest 24-months persistence rate (<jats:italic>p<\/jats:italic>\u2009=\u20090.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Secukinumab improved disease activity in axSpA patients, especially in naive, and second-line patients, which was accompanied by high persistence rates up to 24 months.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2023.1156557","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T06:59:24Z","timestamp":1683874764000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Real-world experience with secukinumab in the entire axial spondyloarthritis spectrum"],"prefix":"10.3389","volume":"10","author":[{"given":"Francisca","family":"Sivera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"N\u00fa\u00f1ez-Monje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Campos-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Balaguer-Trull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Robustillo-Villarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Aguilar-Zamora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Garijo-Bufort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Miguel","family":"L\u00f3pez-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Pe\u00f1a-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"de la Morena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Bedoya-Sanch\u00eds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliya","family":"Yankova-Komsalova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arantxa","family":"Conesa-Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Mart\u00ednez-Crist\u00f3bal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Javier","family":"Navarro-Blasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Miguel","family":"Senabre-Gallego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jos\u00e9","family":"Alegre-Sancho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,11]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"15013","DOI":"10.1038\/nrdp.2015.13","article-title":"Axial Spondyloarthritis","volume":"1","author":"Sieper","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","article-title":"The development of assessment of Spondyloarthritis international society classification criteria for axial Spondyloarthritis (part ii): validation and final selection","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1080\/1744666X.2018.1477591","article-title":"Radiographic progression in non-radiographic axial Spondyloarthritis","volume":"14","author":"Protopopov","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"e000053","DOI":"10.1136\/rmdopen-2015-000053","article-title":"Non-radiographic axial Spondyloarthritis and ankylosing spondylitis: what are the similarities and differences?","volume":"1","author":"Baraliakos","year":"2015","journal-title":"RMD Open"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1093\/rheumatology\/kez119","article-title":"Comorbidity burden in axial Spondyloarthritis: a cluster analysis","volume":"58","author":"Zhao","year":"2019","journal-title":"Rheumatology"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/RHU.0000000000000589","article-title":"Patient burden of axial Spondyloarthritis","volume":"23","author":"Strand","year":"2017","journal-title":"J Clin Rheumatol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"e001108","DOI":"10.1136\/rmdopen-2019-001108","article-title":"Characteristics and burden of disease in patients with radiographic and non-radiographic axial Spondyloarthritis: a comparison by systematic literature review and meta-analysis","volume":"5","author":"L\u00f3pez-Medina","year":"2019","journal-title":"RMD Open"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/ard-2022-223296","article-title":"Asas-Eular recommendations for the management of axial Spondyloarthritis: 2022 update","volume":"82","author":"Ramiro","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fmed.2017.00001","article-title":"Anti-Il17a in axial Spondyloarthritis-where are we at?","volume":"4","author":"Cheung","year":"2017","journal-title":"Front Med (Lausanne)"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an interleukin-17a inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1136\/annrheumdis-2016-210023","article-title":"Secukinumab efficacy in anti-Tnf-naive and anti-Tnf-experienced subjects with active ankylosing spondylitis: results from the measure 2 study","volume":"76","author":"Sieper","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e001005","DOI":"10.1136\/rmdopen-2019-001005","article-title":"Long-term efficacy and safety of Secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase iii measure 1 extension study","volume":"5","author":"Baraliakos","year":"2019","journal-title":"RMD Open"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1186\/s13075-017-1490-y","article-title":"Efficacy, safety, and tolerability of Secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, measure 3","volume":"19","author":"Pavelka","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s40744-018-0123-5","article-title":"Efficacy and safety of Secukinumab 150 mg with and without loading regimen in ankylosing spondylitis: 104-week results from measure 4 study","volume":"5","author":"Kivitz","year":"2018","journal-title":"Rheumatol Ther"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e000592","DOI":"10.1136\/rmdopen-2017-000592","article-title":"Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase iii trial, measure 2","volume":"3","author":"Marzo-Ortega","year":"2017","journal-title":"RMD Open"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/acr.23233","article-title":"Secukinumab and sustained improvement in signs and symptoms of patients with active ankylosing spondylitis through two years: results from a phase iii study","volume":"69","author":"Marzo-Ortega","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/art.41477","article-title":"Improvement of signs and symptoms of nonradiographic axial Spondyloarthritis in patients treated with Secukinumab: primary results of a randomized, placebo-controlled phase iii study","volume":"73","author":"Deodhar","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"ref18","first-page":"50","article-title":"Long-term effects of interleukin-17a inhibition with Secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the phase 3 measure 1 trial","volume":"36","author":"Baraliakos","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1002\/acr.24560","article-title":"Real-world 6 and 12-month drug retention, remission and response rates of Secukinumab in 2,017 psoriatic arthritis patients in 13 European countries","volume":"74","author":"Michelsen","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s40744-022-00446-9","article-title":"Real-world effectiveness and treatment retention of Secukinumab in patients with psoriatic arthritis and axial Spondyloarthritis: a descriptive observational analysis of the Spanish Biobadaser registry","volume":"9","author":"Moreno-Ramos","year":"2022","journal-title":"Rheumatol Ther"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"e001280","DOI":"10.1136\/rmdopen-2020-001280","article-title":"Drug retention, inactive disease and response rates in 1860 patients with axial Spondyloarthritis initiating Secukinumab treatment: routine care data from 13 registries in the Eurospa collaboration","volume":"6","author":"Michelsen","year":"2020","journal-title":"RMD Open"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"adv00698","DOI":"10.2340\/actadv.v102.563","article-title":"Long-term safety of Secukinumab over five years in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis: update on integrated pooled clinical trial and post-marketing surveillance data","volume":"102","author":"Gottlieb","year":"2022","journal-title":"Acta Derm Venereol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13075-019-1882-2","article-title":"Long-term safety of Secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data","volume":"21","author":"Deodhar","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"6983272","DOI":"10.1155\/2020\/6983272","article-title":"Long-term effectiveness of Secukinumab in patients with axial Spondyloarthritis","volume":"2020","author":"Gentileschi","year":"2020","journal-title":"Mediat Inflamm"},{"key":"ref25","first-page":"438","article-title":"Prompt clinical response to Secukinumab in patients with axial Spondyloarthritis: real life observational data from three Italian referral centers","volume":"20","author":"Gentileschi","year":"2018","journal-title":"Isr Med Assoc J"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1093\/rheumatology\/kew238","article-title":"Which aspects of health are most important for patients with Spondyloarthritis? A best worst scaling based on the Asas health index","volume":"55","author":"Kiltz","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1007\/s12325-020-01352-8","article-title":"Secukinumab use in patients with moderate to severe psoriasis, psoriatic arthritis and ankylosing spondylitis in real-world setting in Europe: baseline data from Serena study","volume":"37","author":"Kiltz","year":"2020","journal-title":"Adv Ther"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1136\/annrheumdis-2020-eular.220","article-title":"Thu0399 how do Tnf-alpha-inhibitors in medical history affect patient reported outcomes and retention in ankylosing spondylitis patients treated with Secukinumab in real world? German Aquila Study","volume":"79","author":"Kiltz","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"679009","DOI":"10.3389\/fmed.2021.679009","article-title":"Multicenter study of Secukinumab survival and safety in Spondyloarthritis and psoriatic arthritis: SEcukinumab in Cantabria and ASTURias study","volume":"8","author":"Alonso","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"16","DOI":"10.7399\/fh.11465","article-title":"Persistence of Secukinumab in patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis","volume":"45","author":"Conesa-Nicol\u00e1s","year":"2020","journal-title":"Farm Hosp"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"815881","DOI":"10.3389\/fmed.2021.815881","article-title":"Association of gender, diagnosis, and obesity with retention rate of Secukinumab in Spondyloarthropathies: results form a multicenter real-world study","volume":"8","author":"Garc\u00eda-Dorta","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"ref32","year":""},{"key":"ref33","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/acr2.11102","article-title":"Secukinumab 150\/300 mg provides sustained improvements in the signs and symptoms of active ankylosing spondylitis: 3-year results from the phase 3 measure 3 study","volume":"2","author":"Pavelka","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1136\/annrheumdis-2016-209730","article-title":"Effect of Secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase iii measure 1 study","volume":"76","author":"Braun","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1759720x211041854","DOI":"10.1177\/1759720x211041854","article-title":"Secukinumab in axial Spondyloarthritis: a narrative review of clinical evidence","volume":"13","author":"Braun","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1080\/14712598.2020.1761957","article-title":"One-year effectiveness, retention rate, and safety of Secukinumab in ankylosing spondylitis and psoriatic arthritis: a real-life multicenter study","volume":"20","author":"Chimenti","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1136\/annrheumdis-2019-eular.2829","article-title":"Fri0388 Secukinumab improves health-related quality of life in patients with ankylosing spondylitis, irrespective of time since first diagnosis: pooled results from the Secukinumab phase 3 trial program","volume":"78","author":"Deodhar","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1136\/annrheumdis-2019-eular.284","article-title":"Ab0701 real-world experience of Secukinumab for axial Spondyloarthritis: specific population characteristics","volume":"78","author":"Emperiale","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"ref39","article-title":"Effectiveness and retention rate of Secukinumab for psoriatic arthritis and axial Spondyloarthritis: real-life data from the Italian Lorhen registry [abstract]","author":"Favalli","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s40261-020-00886-7","article-title":"Comparison of the effects of Secukinumab and adalimumab biosimilar on radiographic progression in patients with ankylosing spondylitis: Design of a Randomized, phase Iiib study (Surpass)","volume":"40","author":"Baraliakos","year":"2020","journal-title":"Clin Drug Investig"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"e039059","DOI":"10.1136\/bmjopen-2020-039059","article-title":"Treat-to-target strategy with Secukinumab as a first-line biological disease modifying anti-rheumatic drug compared to standard-of-care treatment in patients with active axial Spondyloarthritis: protocol for a randomised open-label phase iii study, Ascalate","volume":"10","author":"Poddubnyy","year":"2020","journal-title":"BMJ Open"}],"updated-by":[{"DOI":"10.3389\/fmed.2024.1462054","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:00:00Z","timestamp":1725926400000}}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1156557\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T16:52:41Z","timestamp":1725987161000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1156557\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,11]]},"references-count":41,"alternative-id":["10.3389\/fmed.2023.1156557"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1156557","relation":{"corrigendum":[{"id-type":"doi","id":"10.3389\/fmed.2024.1462054","asserted-by":"object"}]},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,11]]},"article-number":"1156557"}}